CLINICAL EFFICIENCY AND SAFETY OF FENOFIBRATE, A PPARα AGONIST, IN THE PATIENTS WITH DIABETESASSOCIATED OSTEOARTHRITIS: A CROSS-OVER PILOT STUDY

Sixteen female patients with diabetes-associated osteoarthritis (DAOA) participated in an openlabel, randomized, cross-over study. The mean patients’ age was 65.5 (±5.4) years, the patients were obese (mean body mass index, 35.8±5.7 kg/m2 ). They suffered from durable osteoarthritis (14.5±7.6 years) associated with diabetes mellitus (13.08±3.43 years). Clinical and radiographic signs of knee OA were observed in 100% of the cases, all the patients had Kellgren–Lawrence grade III radiographic changes. First group of patients (n = 9) was randomized to Fenofibrate (145 mg/day for 12 weeks), the second group (n = 7) received chondroitine sulfate (1000 mg/day for 12 weeks). Then, following a two-week washout period, the first group was switched to chondroitine sulfate and the second group, to fenofibrate. Clinical examination was performed monthly, and laboratory evaluation was performed at the baseline and by the end of each treatment course. pain level according to VAS scale was used as the primary endpoint, whereas KOOS, WOMAC, ICOAP and other scores served as secondary endpoints. We have also assessed effects of Fenofibrate upon serum biomarkers (IL-6, IL-18, IL-10, lipid profiles, and CRP concentrations). Comparative effect of Fenofibrate was evaluated by means of generalized estimating equation (GEE) models adjusted for the treatment sequence. It was shown that clinical effects of Fenofibrate in patients with DAOA did not significantly differ from those of chondroitine sulfate. However, fenofibrate had broader spectrum of effects including improvement of lipid profiles. E.g., Fenofibrate treatment was associated with increased HDL levels (β coefficient, -0.19; р = 0.02), a decrease in total cholesterol (β coefficient, -0.78; р = 0.01), and triglycerides (β coefficient,0.85; р = 0.002). In addition, Fenofibrate therapy was associated with a decrease in ESR, a laboratory biomarker of systemic inflammation (β coefficient, -7.76; р = 0.01). Cytokine changes following the Fenofibrate treatment did not differ from those registered after chondroitine sulfate therapy. In conclusion, the results of this pilot study provide a rationale for further studies of PPARα agonists and their pleiotropic effects in large-scale controlled clinical trials.

1. Анкудинов А.С. Проблемы сердечно-сосудистой коморбидности при остеоартрозе // Современные проблемы ревматологии, 2013. № 5. С. 22-31. [Ankudinov A.S. Problems of cardiovascular comorbidity in osteoarthritis. Sovremennye problemy revmatologii = Modern Problems of Rheumatology, 2013, no. 5, pp. 22-31. (In Russ.)]

2. Бадокин В.В. Клиническая оценка фармакологической активности препарата хондроитина сульфат // Лечащий врач, 2012. № 10. С. 10-13 [Badokin V.V. Clinical assessment of pharmacologic activity of chondroitin sulfate medication. Lechashchiy vrach = The Practitioner, 2012, no. 10, pp. 10-13. (In Russ.)]

3. Березняков И.Г., Корж И.В. Остеоартрит, артериальная гипертензия и ожирение: проблемы ко- морбидности // Международный медицинский журнал, 2012. № 4. С. 78-81. [Bereznyakov I.G., Korzh I.V. Osteoarthrosis, arterial hypertendion, and obesity: comorbidity problem. Mezhdunarodnyy meditsinskiy zhurnal = The International Medical Journal, 2012, no. 4, pp. 78-81. (In Russ.)]

4. Денисов Л.Н., Насонова В.А. Ожирение и остеоартроз // Научно-практическая ревматология, 2011. № 3. С. 48-55. [Denisov L.N., Nasonov V.A. Obesity and osteoarthritis. Nauchno-prakticheskaya revmatologiya = Scientific and Practical Rheumatology, 2011, no. 3, pp. 48-55. (In Russ.)]

5. Наумов А.В., Верткин А.Л., Алексеева Л. И., Шамуплова М.М., Мендель О.А., Лучихина А.В. Остеоартроз и сердечно-сосудистые заболевания. Общие факторы риска и клинико-патогенетические вза- имосвязи // Профилактическая медицина, 2010. № 3. С. 35-41. [Naumov A.V., Vertkin A.L., Alekseeva L.I., Shamuplova M.M., Mendel O.A., Luchikhina A.V. Osteoarthrosis and cardiovascular diseases. Overall risk factors and clinical and pathogenetic Profilakticheskaya meditsina = Preventive Medicine, 2010, no. 3, pp. 35-41. (In Russ.)]

6. Федеральные клинические рекомендации по диагностике и лечению остеоартроза. Ассоциация ревматологов России, 2013. 19 c. [Federal clinical guidelines for the diagnosis and treatment of osteoarthritis. Assotsiatsiya revmatologov Rossii = Association of Rheumatologists of Russia, 2013. 19 p. (In Russ.)]

7. Ширинский В.С., Ширинский И.В. Узловая терапия – новая возможность лечения коморбидных заболеваний // Сибирский медицинский журнал, 2014. Т. 29, № 4. С. 13-21. [Shirinsky V.S., Shirinsky I.V. Hub therapy as a new opportunity for treatment of comorbid diseases. Sibirskiy meditsinskiy zhurnal = Siberian Journal of Medicine, 2014, Vol. 29, no. 4, pp. 13-21. (In Russ.)]

8. Ширинский И.В., Сазонова О.В., Калиновская Н.Ю., Ширинский В.С. Коморбидность, метилирование ДНК и аутоиммунитет при диабет-ассоциированном остеоартрите: поисковое исследование // Медицинская иммунология, 2015. Т. 17, № 4. С. 327-334. [Shirinsky I.V., Sazonova O.V., Kalynovskaya N.Yu., Shirinsky V.S. Comorbidity, DNA methylation and autoimmunity in diabetes-associated osteoarthritis: an exploratory study. Meditsinskaya immunologiya = Medical Immunology (Russia), 2015, Vol. 17, no. 4, pp. 327-334. (In Russ.)] http://dx.doi.org/10.15789/1563-0625-2015-4-327-334

9. Ширинский И.В., Калиновская Н.Ю., Ширинский В.С. Клинико-иммунологическая характеристика диабет-ассоциированного остеоартрита // Медицинская иммунология, 2015. Т. 17, № 1. С. 87-93. [Shirinsky I.V., Kalynovskaya N.Yu., Shirinsky V.S. Clinico and immunological characteristics of diabetes-associated osteoarthritis. Meditsinskaya immunologiya = Medical Immunology (Russia), 2015, Vol. 17, no. 1, pp. 87-92. (In Russ.)] http://dx.doi.org/10.15789/1563-0625-2015-1-87-92

10. Ширинский И.В., Сазонова О.В., Ширинский В.С. Биомаркеры атеросклероза у больных диабет- ассоциированным остеоартритом // Вестник уральской медицинской академической науки, 2014. № 5 (51). С. 23-28. [Shirinsky I.V., Sazonova O.V., Shirinsky V.S. Biomarkers atherosclerosis in patients with diabetesassociated osteoarthritis. Vestnik ural`skoy meditsinskoy akademicheskoy nauki = Bulletin of Ural Medical Academic Science, 2014, no. 5 (51), pp. 23-28. (In Russ.)]

11. Abourbih S., Filion K.B., Joseph L., Schiffrin E.L., Rinfret S., Poirier P., Pilote L., Genest J., Eisenberg M.J. Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review. Ann. Rheum. Dis., 2016, Vol. 75, no. 1, pp. 37-44.

12. Altman R., Asch E., Bloch D., Bole G., Borenstein D., Brandt K. The American College of Rheumatology criteria for the classification and reporting of osteoarthritis of the knee. Arthritis Rheum., 1986, Vol. 29, pp. 1039-1049.

13. Bellamy N., Buchanan W.W., Goldsmith C.H., Campbell J., Stitt L.W. Validation study of WOMAC: a health status instrument for measuring clinically important patient relevant outcomes to antirheumatic drug therapy in patients with osteoarthritis of the hip or knee. J. Rheumatol., 1988, no. 15, pp. 1833-1840.

14. Berenbaum F. Diabetes-induced ostheoarthritis from a new paradigm to a new phenotype. Ann. Rheum. Diseases, 2011, Vol. 70, no. 8, pp. 1354-1356.

15. Calamia V., Ruiz-Romero C., Rocha B., Fernández-Puente P., Mateos J., Montell E., Vergés J., Blanco F.J. Pharmacoproteomic study of the effects of chondroitin and glucosamine sulfate on human articular chondrocytes. Arthritis Res. Ther., 2010, Vol. 12, no. 4, R138.

16. Choirat C., Honaker J., Imai K., King G., Lau O. Zelig: Everyone’s Statistical Software. Version 5.0-12, 2016.

17. Hochberg M.C., Altman R.D., April K.T. American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand,hip, and knee. Arthritis Care Res (Hoboken), 2012, Vol. 64, no. 4, pp. 465-474.

18. Jordan K.M., Arden N.K., Doherty M. EULAR recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for international clinical studies including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis., 2003, no. 62, pp. 1145-1155.

19. Lydersen S. Statistical review: frequently given comments. Ann. Rheum. Dis., 2015, Vol. 74, no. 2, pp. 323-325.

20. McAlindon T.E., Bannuru R.R., Sullivan M.C. OARSI guidelines for the non-surgical management of knee osteoarthritis. Osteoarthritis Cartilage. 2014, Vol. 22, no. 3, pp. 363-388.

21. Moreton B.J., Wheeler M., Walsh D.A., Lincoln N.B. Rasch analysis of the intermittent and constant osteoarthritis pain (ICOAP) scale. Osteoarthritis Cartilage, 2012, Vol. 20, no. 10, pp. 1109-1115.

22. National Clinical Guidelines Centre. Osteoarthritis: The care and management of osteoarthritis in adults. Clinical guideline CG177, 2014.

23. Roos E.M., Roos H.P., Lohmander L.S., Ekdahl C., Beynnon B.D. Knee Injury and Osteoarthritis Outcome Score (KOOS)-development of a self-administered outcome measure. J. Orthop. Sports Phys. Ther., 1998, no. 28, pp. 88-96.

24. Schneider H., Maheu E., Cucherat M.Symptom-modifying effect of chondroitin sulfate in knee osteoarthritis: a meta-analysis of randomized placebo-controlled trials performed with structum. Open Rheumatol. J., 2012, no. 6, pp. 183-189.

25. Shirinsky I.V., Shirinsky V.S. Targeting Nuclear Hormone receptors: PPAR alpha agonists as Potential Disease– Modifing Drugs for Rheumatoid Arthritis. Int. J. Rhematol., 2011, Vol. 2011, Art. 937843.

26. Shirinsky I.V., Shirinsky V.S. Treatment of erosive osteoarthritis with peroxisome proliferator-activated receptor alpha agonist fenofibrate: a pilot study. Rheumatol. Int., 2014, Vol. 34, no. 5, pp. 613-616.

27. Wildi L.M., Raynauld J.P., Martel-Pelletier J., Beaulieu A., Bessette L., Morin F., Abram F., Dorais M., Pelletier J.P. Chondroitin sulphate reduces both cartilage volume loss and bone marrow lesions in knee osteoarthritis patients starting as early as 6 months after initiation of therapy: a randomised, double-blind, placebo-controlled pilot study using MRI. Ann. Rheum. Dis., 2011, Vol. 70, no. 6, pp. 982-989.